Teriflunomide (Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German IQWiG) examined whether teriflunomide offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). This is not the case; although certain side effects occur less frequently under teriflunomide than under interferon beta 1a, others are more frequent. Overall, IQWiG does not regard an added clinical benefit as having been proven.

For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/teriflunomide_in_multiple_sclerosis_added_benefit_not_proven.5368.html